Fennec Pharmaceuticals Inc
Research Fennec Pharmaceuticals Inc (FRX) on Bullrun: market cap CAD 543.19M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFRX
- ExchangeTO
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Market capCAD 543.19M
- Financial periodQ1 2026
- RevenueUSD 15.11M
- Net incomeUSD 201.00K
- Free cash flowUSD 2.38M
- Gross margin96.2%
Valuation Snapshot
latest market cap is CAD 543.19M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 44.64M | -USD 9.74M | -USD 12.47M | 91.6% | -0.34 | USD 36.79M | USD 0 | USD 35.47M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | CAD 543.19M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Fennec Pharmaceuticals Inc's market cap?
Fennec Pharmaceuticals Inc's market capitalization is CAD 543.19M.
What does Fennec Pharmaceuticals Inc do?
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc.